Showing results (381-390 of 391) with videos related to
Sort By:
Pageof 40
Oncology and Therapy|April 30, 2026
Occupational Variation in the Incidence of Laryngeal Cancer in the Nordic CountriesTimo Carpén, Zakarya Hadj-Allal, Rayan Nikkilä, et al.Oncology and Therapy|March 26, 2026
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature ReviewMeral Beksac, Mohamed Samra, Omar Abduljalil, et al.Oncology and Therapy|May 19, 2026
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology PracticePatrick Squires, Ke Meng, Xiaohan Hu, et al.Oncology and Therapy|May 7, 2026
Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion CaptureChristopher Wang, Ajay Prasad, Elizabeth Qi, et al.Oncology and Therapy|May 20, 2026
Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in ItalyGiuseppe Cabibbo, Caterina Cocuzza, Ciro Celsa, et al.Oncology and Therapy|May 21, 2026
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from CroatiaIsidora Curic, Nikola Kotur, Bojan Ristivojevic, et al.Oncology and Therapy|June 11, 2026
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder CancerMichele Musone, Biagio Barone, Stefano Chianese, et al.Oncology and Therapy|June 15, 2026
Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)Giandomenico Roviello, Mattia Alberto Di Civita, Daniele Santini, et al.Oncology and Therapy|June 22, 2026
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLLDaniel A Ermann, Deborah M Stephens, Xiaoliang Wang, et al.Oncology and Therapy|June 26, 2026
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment LandscapeBrian I Rini, Benjamin GarmezyPageof 40